Skip to content

SEC filer · CIK 0001019034 · BKYI

Bio KEY International Inc

Bio KEY International net income: -$7.16 million for the year ending 2025-12-31. Total assets: $8.30 million at 2025-12-31.

Every reported measure

The latest value of each measure the company reports, as filed. Choose one for its full history, its definition and the filing behind each figure. Separate currencies and reporting intervals stay separate rows; these are reported amounts, not prices.

Latest value of each measure
MeasurePeriod startPeriod endValueFiled
Total assets-2025-12-31$8.30 million2026-06-12
Total liabilities-2025-12-31$3.20 million2026-06-12
Stockholders equity-2025-12-31$5.11 million2026-06-12
Cash and cash equivalents-2025-12-31$2.69 million2026-06-12
Net income or loss2025-01-012025-12-31-$7.16 million2026-06-12
Operating cash flow2025-01-012025-12-31-$4.67 million2026-06-12
Capital expenditure payments2025-01-012025-12-31$12.0 thousand2026-06-12
Financing cash flow2025-01-012025-12-31$6.91 million2026-06-12
Investing cash flow2025-01-012025-12-31-$12.0 thousand2026-06-12
Retained earnings or deficit-2025-12-31-$136.5 million2026-06-12
Basic weighted-average shares2025-01-012025-12-31664.8 thousand shares2026-06-12
Basic earnings per share2025-01-012025-12-31-$10.77 per share2026-06-12
Income tax expense or benefit2025-01-012025-12-31$16.5 thousand2026-06-12
Net property, plant and equipment-2025-12-31$67.8 thousand2026-06-12
Operating income or loss2025-01-012025-12-31-$6.83 million2026-06-12
Current assets-2025-12-31$4.54 million2026-06-12
Current liabilities-2025-12-31$3.10 million2026-06-12
Current accounts payable-2025-12-31$507.4 thousand2026-06-12
Net finite-lived intangible assets-2025-12-31$830.1 thousand2026-06-12
Net current accounts receivable-2025-12-31$1.22 million2026-06-12
Operating expenses2025-01-012025-12-31$11.4 million2026-06-12
Net inventory-2025-12-31$370.9 thousand2026-06-12
Gross profit2025-01-012025-12-31$4.56 million2026-06-12
Selling, general and administrative expense2025-01-012025-12-31$6.28 million2026-06-12
Research and development expense2025-01-012025-12-31$2.61 million2026-06-12
Common shares outstanding-2025-12-311.09 million shares2026-06-12
Additional paid-in capital-2025-12-31$141.5 million2026-06-12
Accumulated other comprehensive income or loss-2025-12-31$74.8 thousand2026-06-12
Operating lease right-of-use asset-2025-12-31$48.0 thousand2026-06-12
Operating lease liability-2025-12-31$48.0 thousand2026-06-12
Gross property, plant and equipment-2025-12-31$1.04 million2026-06-12
Accumulated depreciation on property, plant and equipment-2025-12-31$969.2 thousand2026-06-12
Net intangible assets excluding goodwill-2025-12-31$830.4 thousand2026-06-12
Accrued current liabilities-2025-12-31$1.33 million2026-06-12
Prepaid expenses and other current assets-2025-12-31$251.3 thousand2026-06-12
Current contract liabilities-2025-12-31$572.5 thousand2026-06-12
Net deferred tax liabilities-2025-12-31$16.5 thousand2026-06-12
Pre-tax income or loss from continuing operations2025-01-012025-12-31-$7.14 million2026-06-12
Comprehensive income or loss2025-01-012025-12-31-$7.13 million2026-06-12
Depreciation expense2025-01-012025-12-31$84.5 thousand2026-06-12
Amortization of intangible assets2025-01-012025-12-31$267.3 thousand2026-06-12
Nonoperating interest expense2025-01-012025-12-31$60.8 thousand2026-06-12
Nonoperating income or expense2025-01-012025-12-31-$313.8 thousand2026-06-12
Deferred income tax expense or benefit2025-01-012025-12-31$16.5 thousand2026-06-12
Interest paid, net2025-01-012025-12-31$60.8 thousand2026-06-12
Income taxes paid, net2025-01-012025-12-31$02026-06-12
Operating lease payments2025-01-012025-12-31$47.6 thousand2026-06-12
Change in accounts receivable2025-01-012025-12-31$252.6 thousand2026-06-12
Change in inventories2025-01-012025-12-31-$520.8 thousand2026-06-12
Change in accounts payable2025-01-012025-12-31-$310.6 thousand2026-06-12
Older measures: 7 not reported in the two years before 2026-09-20
Measures last reported more than two years before capture
MeasurePeriod startPeriod endValueFiled
Revenue2017-01-012017-12-31$6.30 million2018-04-02
Share-based compensation expense2018-01-012018-12-31$942.7 thousand2019-04-05
Interest expense2023-01-012023-12-31$218.3 thousand2024-06-05
Goodwill carrying amount-2022-12-31$02023-06-01
Cost of revenue2017-01-012017-12-31$3.24 million2018-04-02
Net income available to common stockholders2021-01-012021-12-31-$5.07 million2022-04-01
Proceeds from issuing common stock2018-01-012018-12-31$1.88 million2020-05-14

Filings

63 Bio KEY International filings with published measures: what each annual or quarterly report tagged, with the periods it covered, as reported in that filing. The histories above show the latest-filed value per period.

Inspect the source

Entity
BIO KEY INTERNATIONAL INC / CIK 0001019034
Captured
SEC response SHA-256
3b2eccf1278707a06dd03fc1ca5bba4cb0fbd996f85776a3748003ec5b74f966

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

The MCP server is free and MIT-licensed: npx -y canli-mcp. If these records help your research, a star on GitHub helps other researchers find them.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001019034.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))